Drug Trial Radar · NCT06088004
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
218
Planned (sponsor's estimate)
Start
Sep 28, 2023
Primary completion
Dec 30, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Suzhou Abogen Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Abogen Life Sciences (Shanghai) Co., Ltd.
- First posted
- Oct 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.
Conditions
- Solid Tumor, Adult
Interventions
ABO2011 InjectionDrug
Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
ToripalimabDrug
Anti-PD-1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Incidence and character of DLTsTime frame: monotherapy: 21 days after the first dose. Combination therapy: 28 days after the first dose]
- Phase I: Incidence of Adverse Event (AE)Time frame: monotherapy: from informed consent until 28 days after the last administration. Combination therapy: from informed consent until 90 days after the last administration.
- Phase I: Incidence of Serious Adverse Event (SAE)Time frame: monotherapy: from informed consent until 28 days after the last administration. Combination therapy: from informed consent until 90 days after the last administration.]
- Phase I: Incidence of patients with clinically significant abnormal laboratory resultsTime frame: monotherapy: from the first dose until 28 days of last administration. Combination therapy: from informed consent until 90 days after the last administration.
- Phase II: Objective response ratesTime frame: Estimated to be from time of informed consent up to 2 years
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, China · Recruiting
Shanxi Cancer hospital
Shanxi, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.